期刊文献+

RP-HPLC测定尼麦角林缓释片的含量

Determination of the content of nicergoline in release tablets by RP-HPLC
下载PDF
导出
摘要 目的:建立尼麦角林缓释片的含量测定方法。方法:采用RP-HPLC法,以Agilent ZORBAX C8(250mm×4.6mm,5μm)为色谱柱;乙腈-0.05mol/L磷酸盐缓冲液(42∶58)为流动相;检测波长280nm。结果:尼麦角林在0.243~0.973μg范围内,与峰面积呈良好的线性关系(γ=1.0000);平均回收率为99.8%,RSD为0.64%(n=6)。结论:该法快速、简便、重现性好,可用于尼麦角林缓释片的质量控制。 Objective:To establish a method for determination of contents in Nicergoline Release Tablets. Methods:An RP-HPLC method was used with Agilent ZORBAX C8(250mm×4.6mm,5μm)column;the mobile phase consisted of acetonitrile-0.05mol/L phosphate buffer(42∶58)and UV detection at 280 nm. Results:Nicergoline showed good linear relationship in the range of 0.243~0.973μg(γ =1.0000). The average recovery was 99.8%,RSD was 0.64%(n =6). Conclusions:This method is rapid,simple and reproducible,The method can be used for the quality control of nicergoline release tablets.
出处 《北方药学》 2013年第12期7-8,共2页 Journal of North Pharmacy
关键词 尼麦角林 反相高效液相色谱法 Nicergoline RP-HPLC
  • 相关文献

参考文献4

二级参考文献21

  • 1魏秋玻.尼麦角林联合胞二磷胆碱治疗血管性痴呆的临床研究[J].药学进展,2004,28(9):421-424. 被引量:2
  • 2陈玉山,吴祖舜.脑通和尼莫地平治疗血管性痴呆的疗效比较[J].药学进展,1996,20(2):89-91. 被引量:8
  • 3王梅平,林锦镛,宋丽英.脑通对增进缺血性脑血管病血供的TCD观察[J].海峡药学,1996,8(2):26-27. 被引量:1
  • 4Chen LZ, Wang YQ, Chen N, et al. The medical treatment of senile dementia and advance. Zhongguo Linchuang Kangfu (中国临床康复) 2002:6 ( 21 ) : 3269 - 70.
  • 5Miccheli A, Poccetti C, Capuani G, et al. Glucose entry in neuronal and astrocytic inlemlediary metabolism of aged rals. A sludy of the effects of treatment by 13c NMR spectroscopy. Brain Res 2003; 966 (1): 116 -25.
  • 6Chandra P, Paul A. The effects of nicergoline and other vaso-active substances on molecular biological process in the brain and their effects on the learning abilities of rats//Heidrich H, ed. Proof of Therapeutical Effectiveness of Neurotropic and Vasoactive Drugs. Berlin: Pringer-Verlag 1985:119 - 30.
  • 7Giardino L, Giuliani A, Carfagna N. Neuroprotection and aging of the cholinergic system: a role for the ergoline derivative nicergoline(Sermion).Neuroscience 2002; 109 (3) :487 - 97.
  • 8Vairetti M, Battaglia A, Carfagna N, et al. Antioxidant properties of MDL and MMDL, lwo nicergoline metabolites, during chronic administration of haloperidol. Eur J Pharmacol 2002; 453 ( 1 ) : 69 - 73.
  • 9Alvarez-Guerra M,Bertholom N,Garay RP.Elective blockade by nicergoline of vascular responses elicited by stimulation of alpha I A-adrenoceptor subtype in the rat[J].Fundam Clin Pharmacol,1999,13(1):1-4.
  • 10Benzi G,De Bernardi M,Manzol L,et al.Effect of lysergide and nicergoline on glucose metabolism investigated on the dog brain isolated in situ[J].J Pharm Sci,1972,61:348-352.

共引文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部